Data analyses from two real-world trials of Rebyota (fecal microbiota, live-jslm)efficacy and safety will be presented at IDWeek 2025, according to the details of a recent Ferring Pharmaceuticals news ...
The oral microbiome is home to more than 700 species of bacteria, and the average person hosts approximately 250 species at a time, according to the study. Each person’s oral microbiome is unique and ...
Patients with Type 1 diabetes are often excluded from diabetes and weight loss trials. Forty years ago, the vast majority of patients with Type 1 diabetes didn’t need help with the problem of being ...
These gaps stem from systemic barriers, including limited access to early detection, follow-up delays and inequities in ...
Based on data including more than 788 million patient visits from more than 15,000 ophthalmologists, thousands of eyes were ...
Researchers of the National Eye Institute found that the supplement—now known as the AREDS formula, containing vitamins C and ...
Tzield, a monoclonal antibody approved for stage 2 Type 1 diabetes, now seeks approval for stage 3 disease based on trial ...
Medicare seems to offer more consistent care across states than other insurance programs; however, where beneficiaries live ...
Bandyopadhyay and colleagues found that new T1D registrations were most likely to come from people under the age of 40, ...
Kenneth A. Beckman, M.D., doesn’t see insurers as standing in the way of patients getting treated with the “epi-on” approach ...
The new treatments Gilhooley referred to are calcitonin gene-related peptide (CGRP) inhibitors, a class that includes ...
Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...